Journal Scans
VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function
VMP Is Effective in MM and Reverses Moderate Renal Impairment
MA Dimopoulos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, E Kastritis, M Kropff, MT Petrucci, M Delforge, J Alexeeva, R Schots, T Masszi, M-V Mateos, W Deraedt, K Liu, A Cakana, H van de Velde, JF San Miguel
20090926
2009 Oct 26
J Clin Oncol
VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function
J Clin Oncol. 2009 Oct 26; Epub ahead of print, MA Dimopoulos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, E Kastritis, M Kropff, MT Petrucci, M Delforge, J Alexeeva, R Schots, T Masszi, M-V Mateos, W Deraedt, K Liu, A Cakana, H van de Velde, JF San Miguel
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
In multiple myeloma (MM), renal impairment is a complication of the disease and is associated with poorer outcomes, more advanced disease, and higher rates of comorbidities and complications. The poorer response to treatment in patients with renal impairment may relate to the need to employ lower starting doses, dose reductions, or treatment interruptions. Early treatment of MM, however, can improve renal function. Bortezomib was approved for the first-line treatment of MM on the basis of results...
